Ruxolitinib in conjunction with the HLH-94 protocol for Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in the intensive care unit: A case report

RATIONALE: The HLH-94 protocol is a standard induction treatment for hemophagocytic lymphohistiocytosis. However, about 30% of patients may not respond. Ruxolitinib has been clinically proven to be an effective treatment for hemophagocytic lymphohistiocytosis (HLH). PATIENT CONCERNS: A previously he...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Zoufang, Xie, Jiangbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982154/
https://www.ncbi.nlm.nih.gov/pubmed/33726009
http://dx.doi.org/10.1097/MD.0000000000025188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982154/
https://www.ncbi.nlm.nih.gov/pubmed/33726009
http://dx.doi.org/10.1097/MD.0000000000025188

Ejemplares similares